Home
 /
Papers
 /
Genomics
 /
Single-cell CRISPR activation screens in primary B cells discover gene regulatory mechanisms for hundreds of autoimmune risk loci
Preprint
Open access
V1
Top 1% · Validated by QED

Single-cell CRISPR activation screens in primary B cells discover gene regulatory mechanisms for hundreds of…

Viacheslav A. Kriachkov, Jeralyn Wen Hui Ching, James Lancaster +14 more
March 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.03.01.708923
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Genomics this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

This work solves the long-standing problem of linking non-coding GWAS variants to autoimmune disease by mapping 524 locus–gene connections in primary human B cells and revealing how single variants orchestrate pleiotropic immune networks through REL.

Author perspective

What is the most important insight, discovery, or finding from your paper that you would like other scientists to know?
“

Interpretation of disease-associated genetic variants still relies heavily on statistical inference and modelling to predict causal genes that mediate disease. Using CRISPR-based perturbations of autoimmune risk loci, we were able to map the target genes of hundreds of non-coding risk loci in a disease-relevant immune cell type. Our findings reveal new molecular mechanisms that could underlie dysfunctional immune processes and reveal new potential pleiotropic mechanisms that could help explain shared genetic risk between different autoimmune diseases.

”
Hamish W. King

QED claims analysis

Summary

Single-cell CRISPR activation screens in primary human B cells systematically map 524 cis-regulatory target genes for 378 autoimmune risk loci across 31 diseases, revealing shared genetic architecture through multi-trait variants, cooperative regulatory element interactions, and transcription factor networks that mediate pleiotropy, with validation demonstrating that SLE-associated rs1432296 acts as a gain-of-function variant increasing REL expression to regulate dozens of additional autoimmune risk loci.

See full analysis
Main Claim 1 –

Shared Autoimmune Risk Variants Cluster Diseases and B Cell Mechanisms

Main Claim 2 –

SCANDAL Maps 524 Cis-Regulatory Targets Across 378 Risk Loci

Supporting evidence

  • Tripartite CRISPR-SAM Delivery Enables High-Throughput Primary B Cell Screens
  • Micro-Capture-C Validates Distal, Non-Nearest SCANDAL Gene Targets
  • CRISPR-SAM Reveals CRE-CRE Co-Regulation Between Autoimmune Enhancers
Main Claim 3 –

SLE Variant rs1432296 Gain-of-Function Increases REL Expression

Supporting evidence

  • MPRA Identifies 91 Allele-Specific Autoimmune Variants Including rs1432296
  • REL and Other TFs Bind Many Risk Loci Explaining Pleiotropy

Abstract

Genome-wide association studies (GWAS) have discovered thousands of genetic variants linked to autoimmune disease, and yet the molecular pathways underlying autoimmunity have remained elusive. A key challenge is that >90% of identified GWAS risk loci are in non-coding genomic regions making it difficult to predict their relevance to disease. Here, we have curated fine-mapped non-coding risk variants from over 30 different autoimmune traits including common conditions such as systemic lupus erythematosus (SLE), Crohn’s disease, and multiple sclerosis, and reveal shared genetic signatures between diverse autoimmune diseases. We subsequently performed a high-throughput single-cell multi-omic CRISPR activation screen targeting 763 autoimmune risk loci in primary human B cells (a highly relevant cell type to autoimmune diseases) and discover 524 cis-regulatory target gene effects for 378 risk loci, with many risk loci regulating multiple gene targets. This Single Cell Analysis of Non-coding Distal Autoimmune Loci (SCANDAL) provides a powerful experimental resource linking non-coding risk loci to many disease-relevant genes, including lowly-expressed cytokines and transcription factors for which perturbation effects can be difficult to quantify with other CRISPR-based strategies. We reveal how increased transcriptional activity at one non-coding risk locus can drive transcription at other risk loci within the same regulatory landscape that may be relevant to understand genetic pleiotropy of autoimmune diseases. Finally, we quantified allele-specific effects on target gene expression with massive parallel reporter assays and prime editing to discover a gain-of-function variant associated with SLE that controls expression of the transcription factor REL/cREL which subsequently binds dozens of risk loci and target genes associated with different autoimmune diseases. Our study provides a valuable resource linking non-coding risk loci with their cis-regulatory target genes and advances our understanding of the shared genetic networks and mechanisms involved in autoimmunity.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?